Materialise NV reported its third‑quarter 2025 financial results, showing total revenue of 66,259 kEUR, a 3.5 % decline from 68,652 kEUR in the same period last year. Adjusted EBIT fell to 2,918 kEUR from 4,408 kEUR, and the adjusted EBIT margin slipped to 4.4 % versus 6.4 % year‑over‑year.
The Medical segment led the top‑line, with revenue up 10.3 % to 33,296 kEUR and adjusted EBITDA rising to 10,199 kEUR. In contrast, the Software segment saw revenue drop 7.4 % to 10,286 kEUR and adjusted EBITDA decline to 1,801 kEUR. The Manufacturing segment posted a 17.1 % revenue decline to 22,677 kEUR and an adjusted EBITDA loss of 845 kEUR.
Materialise’s gross profit for the quarter was 37,651 kEUR, giving a gross profit margin of 56.8 %. Net profit was 1,848 kEUR, down from 3,038 kEUR in Q3 2024. Basic and diluted earnings per share from continuing operations were EUR 0.03, compared with EUR 0.05 a year earlier. Cash and cash equivalents rose to 132,022 kEUR, up 29 % from 102,304 kEUR at the end of 2024, while gross debt increased to 64,278 kEUR. The company’s net cash position improved to 67,744 kEUR.
Cash flow from operating activities for the quarter was 10,359 kEUR. Management reiterated its full‑year guidance of 265,000‑280,000 kEUR in revenue and 6,000‑10,000 kEUR in adjusted EBIT. The company highlighted that the medical segment remains a key growth driver, while manufacturing headwinds stem from macro‑economic pressures and declining prototyping demand, particularly in the automotive sector. The software business is transitioning to a cloud‑subscription model, with 83 % of revenue now recurring.
CEO Brigitte de Vet‑Veithen emphasized the company’s strong cash position and ongoing investment in research and development, noting that targeted cost‑control measures and a focus on the medical market will support future growth.
The results underscore Materialise’s resilience in the medical market, offsetting headwinds in manufacturing and a temporary dip in software revenue, and reaffirm the company’s long‑term growth strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.